Study S000117

Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01272973
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 96
Start: 2011-01
Primary completion: 2011-07
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus, Type 2; Healthy
Interventions: DRUG:semaglutide; DRUG:placebo
Results posted: FALSE
Secondary identifiers: OTHER:U1111-1118-0257; EUDRACT_NUMBER:2010-019951-23

Registered primary outcomes

Frequency of adverse events (AEs) [from the first trial related activity (screening visit) and until completion of the post treatment follow-up visit 91-105 days after first dose]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.